Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

AstraZeneca

Status: Completed

Conditions: Upper Gastrointestinal Bleeding

Study type: Observational

Funder types: Industry

Identifiers

NCT01155401

NIS-GRU-NEX-2009/2

Details and patient eligibility

About

The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients

Enrollment: 300 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
• Written informed consent provided prior the start of participation in the study.

Exclusion criteria

• Subjects who are unwilling or unable to provide informed consent.

Trial design

300 participants in 1 patient group

1

Description:

Patients with acute upper gastrointestinal bleeding